431 related articles for article (PubMed ID: 34297962)
1. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.
Yousafzai MT; Karim S; Qureshi S; Kazi M; Memon H; Junejo A; Khawaja Z; Ur Rehman N; Ansari MS; Ali R; Ujjan IU; Lohana HM; Memon NM; Hussain M; Nigar R; Bar-Zeev N; Qamar FN
Lancet Glob Health; 2021 Aug; 9(8):e1154-e1162. PubMed ID: 34297962
[TBL] [Abstract][Full Text] [Related]
2. Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine.
Yousafzai MT; Qamar FN; Shakoor S; Saleem K; Lohana H; Karim S; Hotwani A; Qureshi S; Masood N; Rauf M; Khanzada JA; Kazi M; Hasan R
Clin Infect Dis; 2019 Feb; 68(Suppl 1):S16-S21. PubMed ID: 30767003
[TBL] [Abstract][Full Text] [Related]
3. Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.
Thobani RS; Yousafzai MT; Sultana S; Kazi AM; Jan M; Rafey A; Khan A; Irfan S; Ujjan IU; Brown N; Mårtensson A; Qamar FN
Vaccine; 2022 Aug; 40(36):5391-5398. PubMed ID: 35945044
[TBL] [Abstract][Full Text] [Related]
4. Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan.
Qamar FN; Yousafzai MT; Khaliq A; Karim S; Memon H; Junejo A; Baig I; Rahman N; Bhurgry S; Afroz H; Sami U
Vaccine; 2020 Apr; 38(19):3518-3523. PubMed ID: 32201138
[TBL] [Abstract][Full Text] [Related]
5. Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study.
Qamar FN; Yousafzai MT; Khalid M; Kazi AM; Lohana H; Karim S; Khan A; Hotwani A; Qureshi S; Kabir F; Aziz F; Memon NM; Domki MH; Hasan R
Lancet Infect Dis; 2018 Dec; 18(12):1368-1376. PubMed ID: 30507460
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study.
Batool R; Tahir Yousafzai M; Qureshi S; Ali M; Sadaf T; Mehmood J; Ashorn P; Naz Qamar F
Vaccine; 2021 Sep; 39(40):5858-5865. PubMed ID: 34465474
[TBL] [Abstract][Full Text] [Related]
7. Continued Outbreak of Ceftriaxone-Resistant Salmonella enterica Serotype Typhi across Pakistan and Assessment of Knowledge and Practices among Healthcare Workers.
Nizamuddin S; Ching C; Kamal R; Zaman MH; Sultan F
Am J Trop Med Hyg; 2021 Jan; 104(4):1265-1270. PubMed ID: 33534746
[TBL] [Abstract][Full Text] [Related]
8. The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
Kulkarni PS; Potey AV; Bharati S; Kunhihitlu A; Narasimha B; Yallapa S; Dharmadhikari A; Gavade V; Kamat CD; Mallya A; Sarma AD; Goel S; Pisal SS; Poonawalla CS; Venkatesan R; Jones E; Flaxman A; Kim YC; Pollard AJ;
Lancet; 2024 Apr; 403(10436):1554-1562. PubMed ID: 38555928
[TBL] [Abstract][Full Text] [Related]
9. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Shakya M; Voysey M; Theiss-Nyland K; Colin-Jones R; Pant D; Adhikari A; Tonks S; Mujadidi YF; O'Reilly P; Mazur O; Kelly S; Liu X; Maharjan A; Dahal A; Haque N; Pradhan A; Shrestha S; Joshi M; Smith N; Hill J; Clarke J; Stockdale L; Jones E; Lubinda T; Bajracharya B; Dongol S; Karkey A; Baker S; Dougan G; Pitzer VE; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
Lancet Glob Health; 2021 Nov; 9(11):e1561-e1568. PubMed ID: 34678198
[TBL] [Abstract][Full Text] [Related]
12. Parental acceptance of typhoid conjugate vaccine for children aged 6 months to 15 years in an outbreak setting of Lyari Town Karachi, Pakistan.
Batool R; Yousafzai MT; Qureshi S; Muhammad S; Qazi I; Sadaf T; Ashorn P; Qamar FN
Vaccine; 2023 Aug; 41(37):5376-5382. PubMed ID: 37463829
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
[TBL] [Abstract][Full Text] [Related]
14. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis.
Batool R; Qamar ZH; Salam RA; Yousafzai MT; Ashorn P; Qamar FN
Lancet Glob Health; 2024 Apr; 12(4):e589-e598. PubMed ID: 38485426
[TBL] [Abstract][Full Text] [Related]
18. Population structure of Salmonella enterica Typhi in Harare, Zimbabwe (2012-19) before typhoid conjugate vaccine roll-out: a genomic epidemiology study.
Thilliez G; Mashe T; Chaibva BV; Robertson V; Bawn M; Tarupiwa A; Takawira FT; Kock MM; Midzi S; Mwamakamba LW; Matheu J; Juru A; Kingsley RA; Ehlers MM
Lancet Microbe; 2023 Dec; 4(12):e1005-e1014. PubMed ID: 37952554
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
